Author:
Santana Noemí,Troyano-Rodriguez Eva,Mengod Guadalupe,Celada Pau,Artigas Francesc
Funder
Innovative Medicines Initiative Joint Undertaking
The Innovative Medicines Initiative Joint Undertaking is a public-private partnership between the European Union
the European Federation of Pharmaceutical Industries and Associations
Generalitat de Catalunya
Centro de Investigación Biomédica en Red de Salud Mental
Ministerio de Ciencia e Innovación de España
Reference67 articles.
1. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development;Krystal;Psychopharmacology (Berl),2003
2. Recent advances in the phencyclidine model of schizophrenia;Javitt;Am J Psychiatry,1991
3. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans—psychotomimetic, perceptual, cognitive, and neuroendocrine responses;Krystal;Arch Gen Psychiatry,1994
4. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: A study with ketamine;Malhotra;Biol Psychiatry,1997
5. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis;Newcomer;Neuropsychopharmacology,1999
Cited by
70 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献